武漢佰樂博代理：Research Grade Lorvotuzumab

貨號：DHC98501

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75479.html

產(chǎn)品購買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab))是一種結(jié)合CD56 (NCAM1)的人源化單克隆抗體。Lorvotuzumab可用于合成ADC化合物L(fēng)orvotuzumab mertansine。

通用名：Lorvotuzumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：BB-10901, IMGN901, huN901-DM1

靶點(diǎn);物種：Human CD56/NCAM1

種類:Humanized

受體鑒定:IgG1-kappa

CAS: 1008106-64-6

存儲條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻(xiàn)：

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer. PMID: 34942494

Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. PMID: 24389179

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. PMID: 32914879

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. PMID: 24492307

ADME of antibody-maytansinoid conjugates. PMID: 22875610

Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates. PMID: 26927803

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma. PMID: 30340993

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. PMID: 23798344

Advances in antibody therapeutics targeting small-cell lung cancer. PMID: 29790694

Immunoconjugates against solid tumors: mind the gap. PMID: 21368753

Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis. PMID: 27935326

Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. PMID: 28341109

Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. PMID: 31544840

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. PMID: 23721099

Emerging antibody-drug conjugates for treating lymphoid malignancies. PMID: 28792782

Emerging immune targets for the treatment of multiple myeloma. PMID: 29421983

Monoclonal antibodies in myeloma. PMID: 26452191

Drug-conjugated antibodies for the treatment of cancer. PMID: 23173552

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. PMID: 28321813

Monoclonal antibodies - A new era in the treatment of multiple myeloma. PMID: 26362528

Novel formulations and new mechanisms of delivering chemotherapy. PMID: 24857128

Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. PMID: 24708159

NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target. PMID: 31477684

Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. PMID: 22909934

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. PMID: 26961907

The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. PMID: 23239665